23.21
price down icon0.17%   -0.04
after-market Handel nachbörslich: 23.21
loading
Schlusskurs vom Vortag:
$23.25
Offen:
$23.25
24-Stunden-Volumen:
584.35K
Relative Volume:
0.69
Marktkapitalisierung:
$1.13B
Einnahmen:
$681.75M
Nettoeinkommen (Verlust:
$70.47M
KGV:
16.01
EPS:
1.45
Netto-Cashflow:
$173.19M
1W Leistung:
-2.93%
1M Leistung:
-11.55%
6M Leistung:
+26.62%
1J Leistung:
+2.07%
1-Tages-Spanne:
Value
$22.82
$23.55
1-Wochen-Bereich:
Value
$22.82
$24.36
52-Wochen-Spanne:
Value
$11.16
$27.98

Pacira Biosciences Inc Stock (PCRX) Company Profile

Name
Firmenname
Pacira Biosciences Inc
Name
Telefon
650-242-8052
Name
Adresse
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Name
Mitarbeiter
790
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
PCRX's Discussions on Twitter

Vergleichen Sie PCRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
PCRX
Pacira Biosciences Inc
23.21 1.13B 681.75M 70.47M 173.19M 1.45
Drug Manufacturers - Specialty & Generic icon
RGC
Regencell Bioscience Holdings Ltd
10.36 303.95B 0 -5.87M -767.30K -0.45
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
159.08 74.39B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.26 48.97B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.42 47.39B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
17.05 20.17B 16.54B -1.64B 749.00M -1.45

Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-01-30 Hochstufung Truist Sell → Hold
2024-08-13 Herabstufung Truist Buy → Sell
2024-08-12 Herabstufung JP Morgan Overweight → Underweight
2024-08-12 Herabstufung Piper Sandler Overweight → Neutral
2024-08-12 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2024-08-12 Herabstufung Raymond James Outperform → Mkt Perform
2024-07-03 Herabstufung Barclays Overweight → Equal Weight
2024-03-07 Fortgesetzt JP Morgan Overweight
2023-12-20 Eingeleitet Raymond James Outperform
2023-08-03 Hochstufung TD Cowen Market Perform → Outperform
2023-01-31 Fortgesetzt Wedbush Outperform
2022-10-21 Fortgesetzt Jefferies Buy
2022-01-03 Fortgesetzt JP Morgan Overweight
2021-07-26 Hochstufung JP Morgan Neutral → Overweight
2021-04-21 Fortgesetzt JP Morgan Neutral
2021-04-09 Eingeleitet Berenberg Buy
2021-04-07 Fortgesetzt RBC Capital Mkts Outperform
2021-02-11 Herabstufung Northland Capital Outperform → Market Perform
2021-01-21 Herabstufung SVB Leerink Outperform → Mkt Perform
2020-09-21 Hochstufung Northland Capital Market Perform → Outperform
2020-07-06 Bestätigt Needham Buy
2020-05-27 Eingeleitet Guggenheim Neutral
2020-04-07 Eingeleitet Northland Capital Outperform
2020-03-20 Hochstufung SVB Leerink Mkt Perform → Outperform
2020-02-24 Bestätigt H.C. Wainwright Buy
2020-01-24 Eingeleitet SunTrust Buy
2020-01-23 Eingeleitet SunTrust Buy
2019-11-06 Eingeleitet BTIG Research Buy
2019-06-11 Eingeleitet Barclays Overweight
2019-05-06 Hochstufung Mizuho Underperform → Neutral
2019-05-02 Hochstufung Stifel Sell → Hold
2019-02-01 Herabstufung Mizuho Neutral → Underperform
2018-08-06 Herabstufung BofA/Merrill Buy → Neutral
2018-04-09 Bestätigt H.C. Wainwright Buy
2018-03-21 Bestätigt Mizuho Neutral
2018-02-16 Herabstufung Needham Buy → Hold
2018-01-19 Eingeleitet Seaport Global Securities Buy
2018-01-04 Bestätigt Canaccord Genuity Buy
2018-01-03 Eingeleitet Leerink Partners Mkt Perform
Alle ansehen

Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten

pulisher
Jun 18, 2025

Is the Options Market Predicting a Spike in Pacira BioSciences Stock? - TradingView

Jun 18, 2025
pulisher
Jun 18, 2025

Investors in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) Should Contact the Shareholders Foundation in Connection with Lawsuit - Newswire :) Press Release Distribution

Jun 18, 2025
pulisher
Jun 18, 2025

Pacira BioSciences Debuts Inspiring New Film Highlighting - GlobeNewswire

Jun 18, 2025
pulisher
Jun 18, 2025

Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025 - GlobeNewswire Inc.

Jun 18, 2025
pulisher
Jun 18, 2025

PACIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire

Jun 18, 2025
pulisher
Jun 17, 2025

PACIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Pacira BioSciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Business Upturn

Jun 17, 2025
pulisher
Jun 17, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Jun 17, 2025
pulisher
Jun 16, 2025

When the Price of (PCRX) Talks, People Listen - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 15, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Connect - ACCESS Newswire

Jun 15, 2025
pulisher
Jun 15, 2025

Rhumbline Advisers Sells 9,754 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World

Jun 15, 2025
pulisher
Jun 14, 2025

GAMMA Investing LLC Grows Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World

Jun 14, 2025
pulisher
Jun 13, 2025

Pacira Pharmaceuticals Stockholders Approve Amended Incentive Plan - TipRanks

Jun 13, 2025
pulisher
Jun 12, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Jun 12, 2025
pulisher
Jun 12, 2025

Have Pacira BioSciences Insiders Been Selling Stock? - simplywall.st

Jun 12, 2025
pulisher
Jun 11, 2025

Pacira (PCRX) Shares Promising Long-Term Data for Osteoarthritis Gene Therapy | PCRX Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Pacira BioSciences Unveils Three-Year Clinical Data - GlobeNewswire

Jun 11, 2025
pulisher
Jun 11, 2025

Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Quite Sensibly - simplywall.st

Jun 11, 2025
pulisher
Jun 10, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Jun 10, 2025
pulisher
Jun 08, 2025

Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jun 08, 2025
pulisher
Jun 08, 2025

Pacira BioSciences (NASDAQ:PCRX) Raised to Buy at Wall Street Zen - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 21,781 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World

Jun 08, 2025
pulisher
Jun 05, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Connect - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 05, 2025

Pacira (PCRX) BioSciences Grants Inducement Awards to New Employ - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

Pacira Expands Team: 19 New Hires Receive $1.8M in Stock Awards and Options - Stock Titan

Jun 05, 2025
pulisher
Jun 02, 2025

Two Sigma Investments LP Purchases 45,222 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

Q3 EPS Estimate for Pacira BioSciences Raised by Analyst - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jun 01, 2025
pulisher
May 30, 2025

Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World

May 30, 2025
pulisher
May 30, 2025

Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by ProShare Advisors LLC - Defense World

May 30, 2025
pulisher
May 29, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

May 29, 2025
pulisher
May 29, 2025

Pacira BioSciences’s First Quarter 2025 Misses Estimates - Orthopedics This Week

May 29, 2025
pulisher
May 28, 2025

Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by Nuveen Asset Management LLC - Defense World

May 28, 2025
pulisher
May 26, 2025

Grabar Law Office Investigates Claims on Behalf of - GlobeNewswire

May 26, 2025
pulisher
May 25, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Reach Out - ACCESS Newswire

May 25, 2025
pulisher
May 24, 2025

Trading (PCRX) With Integrated Risk Controls - news.stocktradersdaily.com

May 24, 2025
pulisher
May 24, 2025

Ameriprise Financial Inc. Acquires 194,597 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World

May 24, 2025
pulisher
May 24, 2025

Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Recommendation of “Hold” from Brokerages - Defense World

May 24, 2025
pulisher
May 22, 2025

Pacira BioSciences (NASDAQ:PCRX) adds US$78m to market cap in the past 7 days, though investors from three years ago are still down 57% - Yahoo Finance

May 22, 2025
pulisher
May 21, 2025

Pacira at RBC Conference: Strategic Growth and Gene Therapy Focus - Investing.com

May 21, 2025
pulisher
May 18, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

May 18, 2025
pulisher
May 18, 2025

2025-05-18 | Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation | Press Release - Stockhouse

May 18, 2025
pulisher
May 18, 2025

The Manufacturers Life Insurance Company Sells 458 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World

May 18, 2025
pulisher
May 17, 2025

Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Comerica Bank - Defense World

May 17, 2025
pulisher
May 17, 2025

Northern Trust Corp Buys 145,205 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World

May 17, 2025
pulisher
May 15, 2025

PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Pacira (PCRX) Reports Promising Data on PCRX-201 Gene Therapy fo - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Pacira (PCRX) Reports Promising Data on PCRX-201 Gene Therapy for Knee Osteoarthritis | PCRX Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee - The Manila Times

May 15, 2025
pulisher
May 15, 2025

Pacira BioSciences Presents New Data on the Effects of - GlobeNewswire

May 15, 2025

Finanzdaten der Pacira Biosciences Inc-Aktie (PCRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Pacira Biosciences Inc-Aktie (PCRX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
WILLIAMS KRISTEN
Chief Administrative Officer
Jun 04 '25
Sale
26.24
14,376
377,226
161,574
$14.72
price up icon 2.01%
$9.34
price up icon 1.74%
$129.40
price up icon 1.09%
$295.22
price up icon 1.48%
drug_manufacturers_specialty_generic RDY
$14.88
price down icon 0.40%
$17.05
price up icon 2.46%
Kapitalisierung:     |  Volumen (24h):